-
NouvNeu001, A Phase 1 Stage Chemically Induced Human Dopaminergic Progenitor Cell Therapy for the Treatment of Mid- to Late-stage Parkinson’s Disease
-
Novel ASO Targeting IGHMBP2 Cryptic Splice Variant: Efficacy and Safety
-
Novel In-Clinic Use of Levodopa Inhalation Powder (CVT-301) as an Outpatient Diagnostic Tool for Parkinson’s Disease
-
Novel Partial Gene Deletion in CaCNA1A Presenting with Gait Ataxia, Vertigo, and Abnormal Eye Movements
-
Nutritional Status Implication at 6 Months in Parkinson’s Disease: Follow-Up Results
-
Obsessive-Compulsive Disorder Prevalence in Parkinson’s Disease Caregivers
-
Oculomotor Biomarkers for Cerebellar Ataxia and Severity in Smooth Pursuit
-
Odor-specific symptoms in Parkinson’s disease – UPSIT odor identification status versus clinical severity.
-
Once-Daily Suvecaltamide Pharmacokinetics, Safety, & Tolerability–Phase 1, Randomized, Double-Blind, Multiple Ascending Dose Study
-
One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson’s disease
- « Previous Page
- 1
- …
- 115
- 116
- 117
- 118
- 119
- …
- 181
- Next Page »